[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menieres-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menieres-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,78,101,131,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100424391","deep-phenotyping-of-hearing-instability-disorders-cohort-establishment-biomarker-identification-development-of-novel-phenotyping-measures-and-discovery-of-therapeutic-targets-100424391",false,"NCT04806282","Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets","* NCLUSION CRITERIA:\n\nAffected Adults\n\nIn order to be eligible to participate in this study as a subject with HI, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. All genders, aged 18-80 years\n\n   Diagnosed with hearing instability, defined as documented hearing instability on serial audiometry with sensorineural hearing loss (SNHL) greater than 30 dB HL at one or more frequencies on at least one hearing test. Inclusion will require documentation of clinically significant change in hearing (either worsening or improvement) between at least 2 hearing tests or documentation of a sudden change in hearing. Clinically significant change in hearing will be defined by a change of10 dB at any three frequencies, 15 dB at any two frequencies, or at least 20 dB at one frequency. A sudden change in hearing will be defined as at least a 30 dB difference at 3 consecutive frequencies in the affected ear as compared to the contralateral ear.\n4. No air-bone gaps in excess of 10 dB for 500-4000 Hz indicative of conductive HL in at least 1 ear.\n5. For females of reproductive potential: Negative pregnancy test at start of study\n\nUnaffected Adults\n\nIn order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. All genders, aged 18-80 years\n4. No air-bone gaps in excess of 10 dB for 500-4000Hz indicative of conductive HL in at least one ear.\n5. Normal middle ear function as indicated by normal 226 Hz tympanograms bilaterally, defined as middle ear pressure between plus minus 100 decaPascals, and peak compensated static compliance between 0.3-1.8 milliliters\n6. For females of reproductive potential: Negative pregnancy test at start of study\n\nEXCLUSION CRITERIA:\n\nAffected and unaffected individuals who meet any of the following criteria will be excluded from participation in this study:\n\n1. Presence of non-MRI compatible devices (cardiac pacemaker, meta\\\u003Cspecific devices (e.g., cardiac pacemaker)\n2. Pregnancy or lactation\n3. Known allergic reactions to gadolinium\n4. Febrile illness within 2 weeks that could affect immune profiling\\*\n5. Evidence of active outer or middle ear disease or anomaly (e.g. otitis media, stenotic ear canal, otorrhea)\n6. History of chronic, as defined by fluid in the middle ear for more than 4 months, or recurrent otitis media, as defined by more than 4 episodes of acute otitis media in one year.\n7. Current PE tubes\n8. Bilateral profound (Pure tone average (PTA) \\> 90 dB HL) sensorineural hearing loss\n9. History or diagnosis of a central nervous system disorder, including but not limited to:\n\n   1. Intracranial tumors\n   2. Cerebrovascular disease\n   3. Degenerative CNS disorder\n   4. CNS trauma\n   5. Encephalitis\n   6. Meningitis\n10. Unable to discontinue medications that can interfere with vestibular test results for the 48 hours immediately preceding a vestibular study session. These include any and all anti-dizziness medications (such as Antivert), alcohol, caffeine, prescription pain medications (such as Percocet), prescription headache medications (such as Imitrex), sleeping pills (such as Ambien), anti-seizure medications (such as Topamax), and\u002For antihistamines (such as Benadryl).\n11. Current diagnosis from the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) of schizophrenia, bipolar disorder, or psychosis.\n12. Unstable intercurrent illness that in the judgment of the PI could prevent or confound collection of data.\n\nProspective study subjects who are cognitively impaired and lack consent capacity, will not be enrolled.\n\n\\*Participants suspected of having COVID-19 will be moved to the designated COVID-19 unit and tested for SARS CoV-2 and Respiratory Pathogen Panel per guidance from NIH CC Clinical Practice Safety Guidelines. Possible COVID-19 infections identified by phone screen will not be eligible for study protocol until infection resolved.",true,"ALL","18 Years","80 Years",{"count":20,"type":21},210,"ESTIMATED","OBSERVATIONAL","Background:\n\nDisorders of hearing instability (HI) are poorly characterized and ineffectively treated. HI can cause fluctuations in hearing thresholds and speech understanding. Researchers want to use a specialized form of magnetic resonance imaging (MRI) and blood tests to learn more about HI.\n\nObjective:\n\nTo characterize a cohort of people with HI and to correlate HI with other data, including hearing evaluations, as well as radiologic and immunologic biomarkers of inflammation over time.\n\nEligibility:\n\nAdults ages 18-80 who have symptoms consistent with possible HI.\n\nDesign:\n\nParticipants will be screened with a medical and hearing history and medical record review.\n\nParticipants will have physical exams. Their head and neck will be examined. They will have blood drawn.\n\nParticipants will have hearing tests. They will wear headphones or foam earplugs. They will listen to different tones. They may describe what they hear.\n\nParticipants will have balance tests. They will wear goggles as they watch moving lights or while cold or warm air is blown into their ears. They will sit in a spinning chair in a quiet, dark booth. From a reclining position, they will raise their head while clicking sounds are played into their ears.\n\nParticipants will have MRIs of the inner ear and brain. The MRI scanner is a metal cylinder surrounded by a strong magnetic field. During the MRIs, participants will lie on a table that slides in and out of the scanner. Soft padding or a coil will be placed around their head. They will get a contrast agent through an intravenous catheter.\n\nParticipation will last up to 15 months.\n\n...",[25,26,27],"Meniere's Disease","Enlarged Vestibular Aqueduct Syndrome","Autoimmune Inner Ear Disease",[29,30,31],"Biomarkers","immunoprofiling","Auditory","RECRUITING","2026-06-26",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":36},"2021-08-17",{"date":40,"type":21},"2030-12-31",{"name":42,"class":43},"National Institute on Deafness and Other Communication Disorders (NIDCD)","NIH",1,{"id":46,"slug":4,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100582167","NCT06859788","SPI-1005 for the Treatment of Meniere's Disease (Open Label)","Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease","Inclusion Criteria:\n\n* Adult males\u002Ffemales, 18-75 years of age at the time of enrollment.\n* Diagnosis of probable or definite Meniere's Disease by AAO-HNS Amended 2015 Criteria.\n* At least two of three active symptoms (fluctuating hearing; tinnitus; aural fullness; vertigo or dizziness) of Meniere's disease, within 3 months of study enrollment.\n* Type A tympanogram at screening.\n* Air conduction thresholds ≤ 90 dB at all tested frequencies (250-8000 Hz) in both ears.\n* Subject is willing and able to provide informed consent and perform study procedures and assessments per protocol.\n* Reproductive requirements\n\nExclusion Criteria:\n\n* Current, or within 60 days prior to study enrollment, use of IV or intratympanic ototoxic medications such as chemotherapy including cisplatin, carboplatin, or oxaliplatin; aminoglycoside antibiotics including gentamicin, amikacin, tobramycin, kanamycin, or streptomycin; or loop diuretics including furosemide.\n* History of otosclerosis or vestibular schwannoma.\n* History of significant middle ear or inner ear surgery in the affected ear.\n* Conductive hearing loss with air-bone gap ≥15 dB, otitis media, or mixed hearing loss.\n* Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurological, or psychiatric disease.\n* Current use or within 30 days prior to study enrollment systemic steroids.\n* Current use or within 7 days prior to study enrollment intratympanic steroids.\n* Hypersensitivity or idiosyncratic reaction to compounds related to ebselen or excipients.\n* Female patients who are pregnant or breastfeeding.\n* Participation in another investigational drug or device study within 30 days prior to study consent.\n* Participant resides more than 100 miles from the study site.","75 Years",{"count":53,"type":21},200,"INTERVENTIONAL",[56],"PHASE3","Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.",[25,59],"Ménière's Disease",[61,62,63,64,65,66],"ebselen","hearing loss","tinnitus","vertigo","dizziness","SPI-1005","2026-06-01",{"date":69,"type":36},"2026-06-02",{"date":71,"type":36},"2025-10-29",{"date":73,"type":21},"2026-12",{"name":75,"class":76},"Sound Pharmaceuticals, Incorporated","INDUSTRY",9,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":85,"targetDuration":4,"studyType":54,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":44},"100330858","phase-2-effects-of-anakinra-in-subjects-with-corticosteroid-resistantintolerant-menieres-disease-and-autoimmune-inner-ear-disease-100330858","NCT03587701","Effects of Anakinra in Subjects With Corticosteroid-resistant\u002FIntolerant Meniere's Disease and Autoimmune Inner Ear Disease","A Phase II Placebo Controlled Study of the Effects of Anakinra (Kineret) in Subjects With Corticosteroid-Resistant\u002FIntolerant Meniere's Disease (CR-MD) and Corticosteroid-Resistant\u002FIntolerant Autoimmune Inner Ear Disease Disease (CR-AIED)","Inclusion Criteria:\n\n* meet diagnostic criteria for Autoimmune Inner Ear Disease (AIED) with active deterioration in one ear as defined below\n* SNHL of greater than 30dB at one or more frequencies in the active ear. The contralateral ear may have any hearing threshold that is either stable or worsening, but may not exhibit improvement in response to corticosteroids even if the more active ear declines. Active deterioration is defined as a 15dB decline at one frequency (excluding 250 or 8kHz as a sole indicator) on their audiogram, or 10dB at 2+ frequencies developing in \\> or equal 3 days but \\\u003C or equal 90 days, or if the hearing loss evolved in less than 3 days, the patient displayed features suggestive of an autoimmune disorder\n* Capable of understanding and giving informed consent\n* Have 2 sequential audiograms following the decline in hearing \\>or equal 28 days apart with no demonstrable improvement in hearing following corticosteroid therapy (\\\u003Cor equal 5dB of improvement at any individual frequency (250, 500, 1000, 2000 and 4000Hz) and \\\u003C12% improvement in WRS)\n* Patients must have been treated with oral or IT prednisone with no demonstrable improvement or attempted to be treated and deemed intolerant. Steroid intolerance is defined as unable or unwilling to take corticosteroids because of a prior untoward effect or a current medical condition that would negatively be impacted by steroid use\n* Must have completed steroid therapy, including any intratympanic steroid therapy\n* Meniere's disease defined according to the AAO criteria, with the additional requirement of corticosteroid resistance AND no new diuretics may be instituted or dose increased from 28 days prior to trial enrollment\n* Patients must be fluent in English as all word recognition scores are based on testing in English\n* Patients may have other autoimmune disease(s) Females of childbearing potential, must be practicing a method of birth control considered effective and medically acceptable by the investigator for a minimum of 2 months prior to the study and at least 2 months after last administration of study drug\n* Males similarly must be practicing a method of birth control considered effective and medically acceptable by the investigator for a minimum of 2 months prior to the study and at least 2 months after last administration of study drug\n\nExclusion Criteria:\n\n* Evidence of retrocochlear pathology (vestibular schwannoma) or inner ear malformation (Mondini Malformation or Enlarged Vestibular Aqueduct) based on imaging\n* Prior treatment with gentamicin for Meniere's Disease\n* Most recent decline in hearing occurring \\>90 days prior to trial enrollment\n* Positive test for Muckle-Wells mutation\n* Concurrently receiving methotrexate, TNF-antagonist therapy or any other immunosuppressive therapy\n* Steroid-dependent hearing loss\n* Any immunodeficiency syndrome\n* Active or chronic infections\n* Currently receiving, or having received treatment for a malignancy in the past 3 years\n* Chronic renal insufficiency (a creatinine clearance of \\\u003C49mL\u002Fmin) or chronic renal failure\n* Neutropenia prior to treatment with anakinra\n* Receipt of live vaccine \\\u003C3 months prior to enrollment\n* Previous treatment with an IL-1 antagonist for any clinical indication\n* First-degree relative with a diagnosis of a CAPS disease\n* History of active narcotic abuts, including prescription narcotics\n* Pregnant or lactating females\n* Non-English speaking patients\n* Seropositive for Hepatitis B, C, HIV or tuberculosis on screening, with the exception of presence of antibodies to Hepatitis B in subjects reporting prior vaccination, and presence of positive skin testing for TB in subjects who received BCG in the past\n* History of suicidal ideation, significant depression that resulted in hospitalization, or answers \"yes\" during C-SSR screening\n* Prior participation in any type of clinical trial using a medication that inhibits interleukin-1 activity\n* Known hypersensitivity to E.coli derived products",{"count":86,"type":21},57,[88],"PHASE2","A Phase II randomized, placebo controlled study design of anakinra (Kineret) in corticosteroid-resistant or intolerant Meniere's disease (CR-MD)and corticosteroid-resistant or intolerant autoimmune inner ear disease (CR-AIED) patients. Patients will be randomized by a 2:1 allocation to anakinra or placebo for 42 continuous days. After day 42, a second placebo-controlled period will begin for an additional 42 days. This will be followed by a 264 day observation period, during which, hearing declines may be re-treated with anakinra after 30 days following the initial drug.",[27,25],"2026-04-14",{"date":93,"type":36},"2026-04-15",{"date":95,"type":36},"2019-01-03",{"date":97,"type":21},"2026-12-31",{"name":99,"class":100},"Northwell Health","OTHER",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":111,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":44},"100632775","genetic-and-biohumoral-factors-involved-in-menires-disease-and-their-correlation-with-phenotypes-100632775","NCT07518069","Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes","Genetics and Biohumoral Factors in Menière's Disease","Menière09","Inclusion Criteria:\n\n* Patients with definite Menière's Disease according to the criteria of the Barany Society\n\nExclusion Criteria:\n\n* surgically treated before the examination or if they had undergone intratympanic therapy with steroids or gentamicin",{"count":110,"type":21},250,"6 Months","Aim of this work was to assess the role of polymorphisms belonging to genes involved in the regulation of ionic homeostasis in Caucasian patients with Ménière Disease (MD) and compare results with a cohort of patients affected by vestibular migraine and a cohort of non vestibular subjects",[114,25,115],"Vertigo","Vestibular Migraine",[117,118,119,120,121],"episodic vertigo","Menière's Disease","Vestibular migraine","genetics","biohumoral markers","2026-04-01",{"date":124,"type":36},"2026-04-08",{"date":126,"type":36},"2025-04-09",{"date":128,"type":21},"2027-04-12",{"name":130,"class":100},"IRCCS San Raffaele",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":54,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100574954","phase-2-efficacy-and-safety-of-isosorbide-oral-solution-in-patients-with-menieres-disease-100574954","NCT06765993","Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II\u002FIII Clinical Study of Isosorbide Oral Solution in the Treatment of Meniere's Disease","MD","Inclusion Criteria:\n\n1. Male or female aged ≥18 and ≤65 years old.\n2. Patients with unilateral Meniere's disease who meet the diagnostic criteria for Meniere's disease in the Guidelines for the Diagnosis and Treatment of Meniere's Disease (2017).\n3. At least 3 episodes of vertigo caused by Meniere's disease within 6 months before enrollment.\n4. Those who understand and voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n1. Patients who have had previous ear surgery for Meniere's disease.\n2. People who suffer from vertigo caused by organic lesions of the external, middle or inner ear.\n3. Patients with diseases that the investigators believe may limit the subjects' participation in this trial:\n\n   * patients with acute intracranial hematoma;\n   * patients with hypokalemia (serum potassium \\\u003C lower limit of normal) or severe dehydration (needing infusion, or hospitalization, or life-threatening, requiring emergency treatment);\n   * patients with acute pulmonary edema;\n   * patients with hypotension (systolic blood pressure \\\u003C90 mmHg and\u002For diastolic blood pressure \\\u003C60 mmHg during the screening period);\n   * patients with severe cardiovascular and cerebrovascular diseases: such as New York Heart Association grade III or IV heart failure, myocardial infarction or unstable angina pectoris within the last 6 months, severe heart failure, progressive multifocal leukoencephalopathy, hypertension that is difficult to control with drugs (systolic blood pressure ≥180 mmHg and\u002For diastolic blood pressure ≥100 mmHg), etc.;\n   * patients with major diseases of other important organs that affect their participation in this study.\n4. Patients who need to use diuretics other than trial drugs for a long time after enrollment.\n5. Patients with any of the following conditions are known or found in laboratory tests:\n\n   * serum creatinine (Cr) level is not within the normal range;\n   * human immunodeficiency virus (HIV) test is positive or has acquired immunodeficiency syndrome (AIDS);\n   * active syphilis infection (positive Treponema pallidum antibody and positive non-specific syphilis antibody);\n   * active hepatitis, hepatitis B: HBsAg and\u002For HBcAb are positive and HBV-DNA \\> 500 IU\u002FmL or the lower limit of detection of the research center \\[only when the lower limit of detection of the research center is higher than 500 IU\u002FmL\\]; hepatitis C: HCV antibody is positive and HCV-RNA is positive or greater than the upper limit of normal value.\n6. Patients with known or suspected history of allergy to the investigational drug (isosorbide) and its excipients (sorbitol, lactic acid, saccharin sodium, propylparaben, butylparaben, orange flavor).\n7. Those with a history of drug abuse or alcoholism within 6 months before enrollment.\n8. Patients who have taken any prohibited drugs specified in this protocol for more than 1 week within 4 weeks before the first administration, including but not limited to vestibular suppressants (including antihistamines - promethazine, diphenhydramine, chlorpheniramine, etc., benzodiazepines - diazepam, lorazepam, clonazepam, etc., anticholinergics - scopolamine, atropine, glycopyrrolate, etc., and antidopamines - prochlorperazine, droperidol, etc.), betahistine, diuretics (including thiazide diuretics - hydrochlorothiazide, chlorthalidone, indapamide, indapamide sustained-release tablets, etc., loop diuretics - furosemide, torsemide, etc., potassium-sparing diuretics - amiloride, triamterene, etc.), glucocorticoids (including prednisone, methylprednisolone, betamethasone, beclomethasone propionate, prednisolone, hydrocortisone, dexamethasone, etc.).\n9. Those who received intratympanic injection of gentamicin within the last year.\n10. Patients who have received any other clinical trial drugs\u002Fdevices within 30 days before the first dose.\n11. Pregnant or lactating women, female patients or male patients' partners who plan to become pregnant during the study period and within 6 months after the last dose, and those who are unwilling to use a medically recognized effective contraceptive method (such as intrauterine contraceptive device or condom) during the trial.\n12. Those who are judged by the researchers to be unsuitable for inclusion.","65 Years",{"count":141,"type":21},234,[88,56],"The purpose of this study is to evaluate the efficacy and safety of isosorbide oral solution compared with placebo in people with unilateral Meniere's disease. A total of approximately 234 subjects will be enrolled in this study: 72 subjects in phase Ⅱ and approximately 162 subjects in phase Ⅲ. Patients were randomly assigned to either the experimental group or the control group. The randomization ratios for phase Ⅱ and phase Ⅲ were 1:1 and 2:1, respectively.",[145],"Meniere´s Disease",[147,148,149,150,151],"Meniere´s disease","Attack","Hearing loss","Tinnitus","Isosorbide","NOT_YET_RECRUITING","2025-01-03",{"date":155,"type":36},"2025-01-09",{"date":157,"type":21},"2024-12-30",{"date":159,"type":21},"2027-12-30",{"name":161,"class":76},"Lunan Better Pharmaceutical Co., LTD.",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":18,"enrollmentInfo":170,"targetDuration":4,"studyType":54,"phases":172,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":44},"100516213","phase-1-modulating-auditory-symptoms-and-vertigo-of-menieres-disease-by-non-invasive-mastoid-electric-stimulation-100516213","NCT06001593","Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation","Pilot Study of Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation: Double-blind, Randomized, Sham-controlled, Investigator-initiated Trial","Inclusion Criteria:\n\n* Patients with dizziness (Meniere's) only, who understand the nature of the study and are willing to participate voluntarily.\n* The frequency of the hearing loss is between 250 kHz and 1 kHz.\n* Patients with bilateral 500, 1000, and 2000 Hz hearing threshold averages within 65 dB HL\n* Patients who have received conventional pharmacotherapy for other dizziness conditions with a washout period of 2 months.\n* To be eligible for subjects in the active phase of the disease, there must be at least 1 vertigo attack in the 6 months before study entry.\n* If tests for renal function, electrolytes, etc. are performed and no problems are found\n\nExclusion Criteria:\n\n* Patients with an otologic condition other than Meniere'ss (dizziness) (otitis media, profound hearing loss, hyperacusis, etc.).\n* Patients' conditions that may affect EEG measurements, such as a stroke, brain hemorrhage, or brain tumor.\n* Patients with kidney disease\n* Patients Have or have had a serious medical condition, such as cancer (including leukemia, blood cancers, epilepsy, and neuropsychiatric conditions).\n* Patients with an artificial implant in the body (cochlear implant, hip joint, pacemaker, etc.)\n* Women of childbearing potential, pregnant women, or nursing mothers\n* Patients who can have Injuries or dermatologic abnormalities at the site of application of the equipment.\n* Patients with coronary artery disease, uncontrolled high blood pressure, or other serious medical conditions (including kidney disease).","19 Years",{"count":171,"type":21},120,[173,88],"PHASE1","This study is a Double-blind, Randomized, Sham-controlled, Investigator-initiated trial. To explore the effectiveness of non-invasive inner ear electrical stimulation of the mastoid behind the ear in controlling auditory symptoms and dizziness in patients with Meniere's disease.",[25],[177,178,179],"Electrical stimulation","Electroceutical","Meniere's disease","2024-12-02",{"date":182,"type":36},"2024-12-05",{"date":184,"type":36},"2023-09-18",{"date":186,"type":21},"2025-12-31",{"name":188,"class":100},"Seoul National University Hospital"]